Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, finds that insulin analogues and inhaled insulins will significantly expand the type 1 diabetes drug market. According to a new study from Decision Resources entitled Type 1 Diabetes, adoption of these agents will drive annual growth of 6.4% between 2002 and 2012.

Nektar (formerly Inhale Therapeutic Systems), in collaboration with Pfizer and Aventis, is developing a short-acting, dry-powder insulin formulation called Exubera, the anticipated first-to-market for inhaled insulins.

"Unlike conventional dry-powder inhalers, Nektar's Inhance dry-powder inhaler technology is designed to deliver the correct dosage independent of the patient's inspiratory flow rate," said Carole Gleeson, analyst at Decision Resources. "While thought leaders are enthusiastic about the potential for a more convenient method of delivery, adverse side effects, namely pulmonary fibrosis, remain a major concern."

Toward the end of the study period, insulin analogues and inhaled insulins may face strong competition from the introduction of orally-available insulins, which mimic the natural secretion pathway of endogenous insulin.

About Type 1 Diabetes

Type 1 diabetes is a disease characterized by total insulin deficiency that results from autoimmune destruction of the insulin-secreting pancreatic beta cells. Although it accounts for less than 10% of all diabetes cases, type 1 diabetes is associated with a high burden of illness and relatively poor quality of life for many patients.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies that assesses a host of market- impacting factors and analyzes the commercial outlook for drugs in research and development.

About Decision Resources

Decision Resources, Inc., (www.decisionresources.com) is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563    emarshall@dresources.com 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-
2563, emarshall@dresources.com

Restrictions by Health Insurers and Government Health Authorities May Hurt the Malignant Melanoma Drug Market

View Now